Article thumbnail
Location of Repository

Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study

By Yayoi Nishida, Yasuo Takahashi, Tomohiro Nakayama, Masayoshi Soma and Satoshi Asai
Topics: Original Investigation
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2011). Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol
  2. (2007). Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol
  3. (1998). Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes.
  4. (1995). Aviram M: Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis
  5. (2009). Bangalore S: Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag
  6. (2010). CA: Renal protection in diabetes: lessons from ONTARGET. Cardiovasc Diabetol
  7. (2003). CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet
  8. (2007). CHARM Program Investigators: Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. JA m Coll Cardiol
  9. (2001). Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
  10. (1983). DB: The central role of the propensity score in observational studies for causal effects. Biometrika
  11. (2009). Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
  12. (2010). Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol
  13. (2010). EK: Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.
  14. (2004). EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation
  15. (2006). FE: Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model
  16. (2003). Fogari R: A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther
  17. (1997). Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression.
  18. (2006). Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: Effects of angiotensin II blockade.
  19. (2001). Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
  20. (2000). Marginal structural models and causal inference in epidemiology. Epidemiology
  21. (2007). MORE study investigators: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin IIreceptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis
  22. (2008). Mugellini A: Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res
  23. (2001). RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
  24. (2003). Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension
  25. (2005). Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res
  26. (1999). Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation
  27. (2006). Stefanadis CI: Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol
  28. (2007). Thiebaud P: Using propensity score to adjust for treatment selection bias. SAS Global forum
  29. (1998). Tutorial on biostatistics: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med
  30. Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.
  31. (2011). Viberti G: ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.